MXCT

MaxCyte, Inc.

4.64 USD

Last updated Nov 28, 12:04 UTC

Yesterday HIGH

$4.72

Yesterday LOW

$4.53

52w HIGH

$6.43

52w LOW

$2.45

EPS

-0.11

PE

-42.18

Next Earnings

Mar 13, 2024

Overview News Insider Transactions Government Trades

MaxCyte, Inc. stock is up 56.76% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 3 November’s closed higher than October.

MaxCyte, Inc. engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Stock Exchange

NASDAQ

Sector

Services

Industry

Business Services

Headquarters

-

Website

maxcyte.com

Benzinga Insights

Wed Aug 9, 2023

Earnings Scheduled For August 9, 2023

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earnings at $0.96 per share on revenue of $18.11 billion.
Benzinga Newsdesk

Tue Aug 1, 2023

MaxCyte Signed A Partnership With Prime Medicine, Granting Non-Exclusive Clinical, Commercial Rights To Use MaxCyte's Flow Electroporation Technology, ExPERT Platform; In Return, MaxCyte Is Entitled To Receive Annual License Fees, Program-Related Revenue
Happy Mohamed

Mon Jul 10, 2023

MaxCyte And Vittoria Biotherapeutics Sign Strategic Platform License To Advance Next Generation Cellular Therapies

MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based
Benzinga Newsdesk

Thu Jul 6, 2023

MaxCyte Signs Strategic Platform License With Lyell Immunopharma; Lyell Immunopharma Obtains Non-Eexclusive Clinical And Commercial Rights To Use MaxCyte's Technology; MaxCyte Receives Fees And Payments

Lyell Immunopharma to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform in its T cell product candidates targeting solid tumors. Under the terms of the agreement, Lyell Immunopharma
Lisa Levin

Thu May 11, 2023

Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.
Lisa Levin

Thu May 11, 2023

Disney, Sonos, Desktop Metal And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Sonos, Inc. (NASDAQ: SONO) shares dipped 25.2% to $15.82 in pre-market trading after the company issued weak FY23 revenue guidance.
Benzinga Insights

Wed May 10, 2023

Recap: MaxCyte Q1 Earnings
Michael Horton

Wed May 10, 2023

MaxCyte Sees FY23 Revenue Up 8%-12% From 2022
Michael Horton

Wed May 10, 2023

MaxCyte Q1 EPS $(0.11), Inline, Sales $8.58M Beat $8.32M Estimate

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 175 percent decrease over losses of $(0.04) per share from the same period last year. The company
Benzinga Insights

Wed May 10, 2023

Earnings Scheduled For May 10, 2023

Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earnings at $0.42 per share on revenue of $851.81 million.